ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Johnson & Johnson and Sichuan Biokin Pharmaceutical side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Johnson & JohnsonSichuan Biokin Pharmaceutical
studies on the registry3,709146
open to participants now146100
phase 3 studies under way9536
reach primary completion within a year8750
programswith a study of their own in two years56+4 named only19

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseJohnson & JohnsonSichuan Biokin Pharmaceutical
Phase 1

Johnson & Johnson: 26 of its 56 programs at phase 1

  1. Anti-CD79b/CD20/CD3 Trispecific Antibody JNJ-80948543phase 1
  2. Anti-PSMA Antibody-drug Conjugate ARX517phase 1
  3. JNJ-86974680phase 1
  4. JNJ-87801493phase 1
  5. JNJ-64264681phase 1

and 21 more — sign in to see them all

46%

Sichuan Biokin Pharmaceutical: 8 of its 19 programs at phase 1

  1. SI-B036phase 1
  2. BL-M24D1phase 1
  3. GNC-077phase 1
  4. Antibody-drug Conjugate BL-M17D1phase 1
  5. BL-ARC002phase 1

and 3 more — sign in to see them all

42%
Phase 2

Johnson & Johnson: 8 of its 56 programs at phase 2

  1. JNJ-95597528phase 2
  2. anvatabart opadotinphase 2
  3. fludarabinephase 2
  4. JNJ-64042056phase 2
  5. JNJ-88545223phase 2

and 3 more — sign in to see them all

14%

Sichuan Biokin Pharmaceutical: 4 of its 19 programs at phase 2

  1. BL-M08D1phase 2
  2. emfizatamabphase 2
  3. BL-M09D1phase 2
  4. glecirasibphase 2
21%
Phase 3

Johnson & Johnson: 18 of its 56 programs at phase 3

  1. amivantamabphase 3
  2. nipocalimabphase 3
  3. ramantamigphase 3
  4. icotrokinraphase 3
  5. lumateperonephase 3

and 13 more — sign in to see them all

32%

Sichuan Biokin Pharmaceutical: 7 of its 19 programs at phase 3

  1. izalontamab brengitecanphase 3
  2. trastuzumab brengitecanphase 3
  3. Anti-CD33 Antibody-drug Conjugate BL-M11D1phase 3
  4. Anti-DLL3 Antibody-drug Conjugate BL-M14D1phase 3
  5. Cytarabinephase 3

and 2 more — sign in to see them all

37%
Approved, new studies

Johnson & Johnson: 4 of its 56 programs at approved, new studies

  1. guselkumabapproved, new study
  2. teclistamabapproved, new study
  3. ibrutinibapproved, new study
  4. Esketamineapproved, new study
7%
00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Johnson & Johnson25 readouts · 8 phase 3·

Johnson & Johnson, Dec ’26: 9 programs whose next study reaches primary completion, 4 in phase 3

  1. anvatabart opadotinphase 2 · Dec 0 · NCT04829604
  2. milvexianphase 3 · Dec 8 · NCT05757869
  3. JNJ-89862175phase 1 · Dec 15 · NCT07223125
  4. nipocalimabphase 3 · Dec 15 · NCT05327114
  5. JNJ-64042056phase 2 · Dec 22 · NCT06544616

and 4 more — sign in to see them all

Johnson & Johnson, Jan ’27: 1 program whose next study reaches primary completion

  1. JNJ-86974680phase 1 · Jan 7 · NCT07319871

Johnson & Johnson, Feb ’27: 4 programs whose next study reaches primary completion, 3 in phase 3

  1. guselkumabapproved, new study · Feb 10 · NCT06260163
  2. icotrokinraphase 3 · Feb 10 · NCT06807424
  3. lazertinibphase 3 · Feb 12 · NCT04077463
  4. teclistamabapproved, new study · Feb 12 · NCT07030517

Johnson & Johnson, Mar ’27: 3 programs whose next study reaches primary completion

  1. Anti-ENPP3/Anti-CD3 Bispecific Antibody JNJ-87890387phase 1 · Mar 16 · NCT06178614
  2. deulumateperonephase 3 · Mar 16 · NCT06480383
  3. pasritamigphase 3 · Mar 31 · NCT04898634

Johnson & Johnson, Apr ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. lumateperonephase 3 · Apr 5 · NCT05850689
  2. ramantamigphase 3 · Apr 19 · NCT05652335
·

Johnson & Johnson, Jun ’27: 4 programs whose next study reaches primary completion

  1. Anti-CALRmut/Anti-CD3 Bispecific Antibody JNJ-88549968phase 1 · Jun 14 · NCT06150157
  2. Anti-PSMA/Anti-CD28 Bispecific Antibody JNJ-87189401phase 3 · Jun 21 · NCT06095089
  3. Aticaprantphase 3 · Jun 21 · NCT07615426
  4. JNJ-88545223phase 2 · Jun 28 · NCT07321873
·

Johnson & Johnson, Aug ’27: 1 program whose next study reaches primary completion

  1. JNJ-90189892phase 1 · Aug 5 · NCT06651229
·

Johnson & Johnson, Oct ’27: 1 program whose next study reaches primary completion

  1. JNJ-88998377phase 1 · Oct 29 · NCT06470438
Sichuan Biokin Pharmaceutical8 readouts · 1 phase 3

Sichuan Biokin Pharmaceutical, Nov ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. izalontamab brengitecanphase 3 · Nov 0 · NCT06118333

Sichuan Biokin Pharmaceutical, Dec ’26: 4 programs whose next study reaches primary completion

  1. Anti-CD33 Antibody-drug Conjugate BL-M11D1phase 3 · Dec 0 · NCT05924750
  2. BL-M08D1phase 2 · Dec 0 · NCT06718621
  3. emfizatamabphase 2 · Dec 0 · NCT05623982
  4. trastuzumab brengitecanphase 3 · Dec 0 · NCT06114511
·

Sichuan Biokin Pharmaceutical, Feb ’27: 1 program whose next study reaches primary completion

  1. Anti-Claudin 18.2 Antibody-drug Conjugate BL-M05D1phase 1 · Feb 28 · NCT07021066
··

Sichuan Biokin Pharmaceutical, May ’27: 1 program whose next study reaches primary completion

  1. BL-M09D1phase 2 · May 0 · NCT06954077

Sichuan Biokin Pharmaceutical, Jun ’27: 1 program whose next study reaches primary completion

  1. GNC-077phase 1 · Jun 0 · NCT06755242
····
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 23, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Johnson & Johnson

New programs 1

Reached a new phase 2

Study stopped 0

None

Primary completion later 3

Sichuan Biokin Pharmaceutical

New programs 2

  • SI-B037phase 1 · first study · Nov 10
  • glecirasibphase 2 · first study · Sep 14 · Carcinoma, Non-Small-Cell Lung

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 1

Where they overlap

Conditions where at least two of them have programs: 14 in all, the first 12 here. A program counts in each condition its studies name most.

ConditionJohnson & JohnsonSichuan Biokin Pharmaceutical
Carcinoma, Non-Small-Cell Lungboth · compare here

Johnson & Johnson in Carcinoma, Non-Small-Cell Lung: 6 programs

  1. amivantamabphase 3
  2. lazertinibphase 3
  3. hafnium oxidephase 3
  4. anvatabart opadotinphase 2
  5. olomorasibphase 2

and 1 more — sign in to see them all

Their studies: Johnson & Johnson’s studies of Carcinoma, Non-Small-Cell Lung in search

Sichuan Biokin Pharmaceutical in Carcinoma, Non-Small-Cell Lung: 9 programs

  1. izalontamab brengitecanphase 3
  2. trastuzumab brengitecanphase 3
  3. PD-1/VEGF Bispecific Antibodyphase 3
  4. BL-M09D1phase 2
  5. glecirasibphase 2

and 4 more — sign in to see them all

Their studies: Sichuan Biokin Pharmaceutical’s studies of Carcinoma, Non-Small-Cell Lung in search

Leukemia, Myeloid, Acuteboth · compare here

Johnson & Johnson in Leukemia, Myeloid, Acute: 11 programs

  1. bleximenibphase 3
  2. Anti-CD79b/CD20/CD3 Trispecific Antibody JNJ-80948543phase 1
  3. JNJ-87801493phase 1
  4. JNJ-64264681phase 1
  5. safimaltibphase 1

and 6 more — sign in to see them all

Their studies: Johnson & Johnson’s studies of Leukemia, Myeloid, Acute in search

Sichuan Biokin Pharmaceutical in Leukemia, Myeloid, Acute: 3 programs

  1. Anti-CD33 Antibody-drug Conjugate BL-M11D1phase 3
  2. Cytarabinephase 3
  3. Daunorubicinphase 3

Their studies: Sichuan Biokin Pharmaceutical’s studies of Leukemia, Myeloid, Acute in search

Lymphoma, Non-Hodgkinboth · compare here

Sichuan Biokin Pharmaceutical in Lymphoma, Non-Hodgkin: 1 program

  1. emfizatamabphase 2

Their studies: Sichuan Biokin Pharmaceutical’s studies of Lymphoma, Non-Hodgkin in search

Breast Neoplasmsboth · compare here

Sichuan Biokin Pharmaceutical in Breast Neoplasms: 6 programs

  1. izalontamab brengitecanphase 3
  2. trastuzumab brengitecanphase 3
  3. SI-B036phase 1
  4. GNC-077phase 1
  5. Antibody-drug Conjugate BL-M17D1phase 1

and 1 more — sign in to see them all

Their studies: Sichuan Biokin Pharmaceutical’s studies of Breast Neoplasms in search

Multiple Myelomaboth · compare here

Johnson & Johnson in Multiple Myeloma: 6 programs

  1. ramantamigphase 3
  2. fludarabinephase 2
  3. JNJ-102299639phase 1
  4. JNJ-87562761phase 1
  5. teclistamabapproved, new study

and 1 more — sign in to see them all

Their studies: Johnson & Johnson’s studies of Multiple Myeloma in search

Sichuan Biokin Pharmaceutical in Multiple Myeloma: 1 program

  1. BL-M24D1phase 1

Their studies: Sichuan Biokin Pharmaceutical’s studies of Multiple Myeloma in search

Prostatic Neoplasmsboth · compare here

Sichuan Biokin Pharmaceutical in Prostatic Neoplasms: 1 program

  1. Lutetium-177phase 1

Their studies: Sichuan Biokin Pharmaceutical’s studies of Prostatic Neoplasms in search

Colorectal Neoplasmsboth · compare here

Johnson & Johnson in Colorectal Neoplasms: 3 programs

  1. amivantamabphase 3
  2. olomorasibphase 2
  3. JNJ-89402638phase 1

Their studies: Johnson & Johnson’s studies of Colorectal Neoplasms in search

Sichuan Biokin Pharmaceutical in Colorectal Neoplasms: 1 program

  1. trastuzumab brengitecanphase 3

Their studies: Sichuan Biokin Pharmaceutical’s studies of Colorectal Neoplasms in search

Squamous Cell Carcinoma of Head and Neckboth · compare here

Johnson & Johnson in Squamous Cell Carcinoma of Head and Neck: 2 programs

  1. amivantamabphase 3
  2. hafnium oxidephase 3

Their studies: Johnson & Johnson’s studies of Squamous Cell Carcinoma of Head and Neck in search

Sichuan Biokin Pharmaceutical in Squamous Cell Carcinoma of Head and Neck: 2 programs

  1. BL-M08D1phase 2
  2. BL-M24D1phase 1

Their studies: Sichuan Biokin Pharmaceutical’s studies of Squamous Cell Carcinoma of Head and Neck in search

Lymphoma, Large B-Cell, Diffuseboth · compare here

Johnson & Johnson in Lymphoma, Large B-Cell, Diffuse: 1 program

  1. ibrutinibapproved, new study

Their studies: Johnson & Johnson’s studies of Lymphoma, Large B-Cell, Diffuse in search

Sichuan Biokin Pharmaceutical in Lymphoma, Large B-Cell, Diffuse: 2 programs

  1. BL-M08D1phase 2
  2. emfizatamabphase 2

Their studies: Sichuan Biokin Pharmaceutical’s studies of Lymphoma, Large B-Cell, Diffuse in search

Arthritis, Rheumatoidboth · compare here

Johnson & Johnson in Arthritis, Rheumatoid: 1 program

  1. nipocalimabphase 3

Their studies: Johnson & Johnson’s studies of Arthritis, Rheumatoid in search

Sichuan Biokin Pharmaceutical in Arthritis, Rheumatoid: 1 program

  1. emfizatamabphase 2

Their studies: Sichuan Biokin Pharmaceutical’s studies of Arthritis, Rheumatoid in search

Hematologic Neoplasmsboth · compare here

Johnson & Johnson in Hematologic Neoplasms: 1 program

  1. teclistamabapproved, new study

Their studies: Johnson & Johnson’s studies of Hematologic Neoplasms in search

Sichuan Biokin Pharmaceutical in Hematologic Neoplasms: 1 program

  1. Daunorubicinphase 3

Their studies: Sichuan Biokin Pharmaceutical’s studies of Hematologic Neoplasms in search

Lupus Erythematosus, Systemicboth · compare here

Johnson & Johnson in Lupus Erythematosus, Systemic: 1 program

  1. nipocalimabphase 3

Their studies: Johnson & Johnson’s studies of Lupus Erythematosus, Systemic in search

Sichuan Biokin Pharmaceutical in Lupus Erythematosus, Systemic: 1 program

  1. emfizatamabphase 2

Their studies: Sichuan Biokin Pharmaceutical’s studies of Lupus Erythematosus, Systemic in search

Show all 14

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: Johnson & Johnson 33 of 56 · Sichuan Biokin Pharmaceutical 9 of 19 programs (20 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Johnson & Johnson: 4).